The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems, providing an alternative to comparator products and lowering price ...
Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs). The FDA has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results